Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mutations and Metabolic Factors Affecting Interaction of Toxigenic and Atoxigenic <i>Aspergillus flavus</i>.

Microorganisms·2026

Same author

Alternative ankle-brachial assessments show no significant added value in predicting mortality of hypertensive patients.

Journal of hypertension·2026

Same author

Efficacy and Safety of Daratumumab, Lenalidomide and Dexamethasone Therapy in the First Relapse of Multiple Myeloma Patients - Real World Data from Hungary.

Journal of hematology·2026

Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Alzheimer's Imaging Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Synthesis of Bio-Based Polyurethanes from Functionalized Sunflower Seed Oil.

International journal of molecular sciences·2025

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Quinapril improves endothelial function in postmenopausal hypertensive patients.

Katalin Farkas¹, Emília Fábián, Lajos Nagy

¹Department of Angiology, Szent Imre Teaching Hospital, Budapest, Hungary. katalin.farkas@sztimrehosp.hu

Kidney & Blood Pressure Research

|July 1, 2008

Summary

Quinapril significantly improved endothelial function in hypertensive postmenopausal women, as measured by flow-mediated dilation (FMD). This suggests that targeting the renin-angiotensin system with quinapril may reduce cardiovascular risk in this population.

Related Experiment Videos

Last Updated: Jul 4, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

Cardiovascular Medicine
Pharmacology
Endocrinology

Background:

Hypertension is a major cardiovascular risk factor, particularly in postmenopausal women.
Postmenopausal women experience reduced endothelium-dependent dilation, indicated by decreased brachial artery flow-mediated dilation (FMD).

Purpose of the Study:

To assess the impact of quinapril on FMD in hypertensive postmenopausal women.
To evaluate dose-dependent changes in endothelial function during a 6-month quinapril treatment.

Main Methods:

A multicenter, open-label, non-comparative study.
61 hypertensive postmenopausal outpatients were enrolled.
Treatment involved increasing doses of quinapril (10, 20, 40 mg) over 6 months.

Main Results:

Baseline mean FMD was 2.83%.
FMD significantly increased with quinapril: 5.58% (10 mg), 7.06% (20 mg), and 8.07% (40 mg) (p < 0.001 for all doses).
All tested doses of quinapril demonstrated significant improvement in FMD compared to baseline.

Conclusions:

Quinapril effectively improves endothelial function in hypertensive postmenopausal women at all tested doses.
Modulating the renin-angiotensin system via quinapril may be a viable strategy for reducing cardiovascular risk in this demographic.